162 related articles for article (PubMed ID: 35662647)
1. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
[TBL] [Abstract][Full Text] [Related]
2. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
3. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells.
Ghalehno AD; Abdi H; Boustan A; Jamialahmadi K; Mosaffa F
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3723-3732. PubMed ID: 37310508
[TBL] [Abstract][Full Text] [Related]
5. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
6. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of SOX11 enhances tamoxifen resistance and promotes epithelial-to-mesenchymal transition via slug in MCF-7 breast cancer cells.
Xiao Y; Xie Q; Qin Q; Liang Y; Lin H; Zeng D
J Cell Physiol; 2020 Oct; 235(10):7295-7308. PubMed ID: 32043610
[TBL] [Abstract][Full Text] [Related]
8. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
[TBL] [Abstract][Full Text] [Related]
10. EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer.
Xie Y; Han X; Yu J; Yuan M; Yan Y; Qin J; Lan L; Wang Y
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18103-18117. PubMed ID: 37999751
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer.
Lee J; Kim EA; Kang J; Chae YS; Park HY; Kang B; Lee SJ; Lee IH; Park JY; Park NJ; Jung JH
BMC Mol Cell Biol; 2024 Apr; 25(1):12. PubMed ID: 38649821
[TBL] [Abstract][Full Text] [Related]
12. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T
J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868
[TBL] [Abstract][Full Text] [Related]
13. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
Watanabe T; Oba T; Tanimoto K; Shibata T; Kamijo S; Ito KI
PLoS One; 2021; 16(6):e0252822. PubMed ID: 34101751
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
16. HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
Kim CY; Kim YC; Oh JH; Kim MH
Anticancer Res; 2021 Jul; 41(7):3409-3417. PubMed ID: 34230136
[TBL] [Abstract][Full Text] [Related]
17. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
[TBL] [Abstract][Full Text] [Related]
18. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
19. CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen-dependent and independent proliferation.
Wu X; Sun A; Yu W; Hong C; Liu Z
Mol Cell Endocrinol; 2020 Jul; 512():110866. PubMed ID: 32417506
[TBL] [Abstract][Full Text] [Related]
20. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]